Skip to main content

Advertisement

SpringerLink
Log in

Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Somatostatin receptor 2a (SSTR2a) is an important diagnostic and scintigraphic marker in several tumors, as well as a potential therapeutic target. However, the expression and clinicopathologic significance of SSTR2a in nasopharyngeal carcinoma (NPC) remain unknown. The expression of SSTR2a was retrospectively analyzed in a large series of NPC tissue samples (106 primary NPC samples, comprising 99 primary non-keratinizing NPC (NK-NPC) and 7 keratinizing NPC (K-NPC) samples, and 41 metastatic NPC samples) by immunohistochemistry, with 24 cases of normal nasopharyngeal mucosa tissues used as a control group. Normal epithelia in nasopharyngeal mucosa were negative for SSTR2a in all 24 cases. The expression of SSTR2a in primary NPC was correlated to the histological subtype. Most cases of primary NK-NPC showed expression of SSTR2a (93.9%, 93/99 cases). The percentage of SSTR2a-positive tumor cells ranged from 10 to 100%, while the intensity ranged from 2+ to 4+. None of the primary K-NPC samples showed SSTR2a expression (0/7, 100%). All cases of NPC showed negative expression of other neuroendocrine markers, including synaptophysin, chromogranin A, and CD56. Of all 41 cases of metastatic NK-NPC lesions, SSTR2a expression is concordant with that of the primary lesions, which shows statistical significance (p < 0.001). Our observations expand the spectrum of recognized SSTR2a-positive tumors and demonstrate for the first time that SSTR2a is frequently expressed in primary and metastatic NK-NPC, highlighting its potential as a scintigraphic and therapeutic target in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zalatnai A, Galambos E, Perjési E (2018) Importance of immunohistochemical detection of somatostatin receptors. Pathol Oncol Res 25:521–525

    Article  Google Scholar 

  2. Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Bressenot AM, Gauchotte G (2017) Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics. J Neuropathol Exp Neurol 76:289–298

    Article  CAS  Google Scholar 

  3. Tao LL, Huang YH, Chen YL, Yu GY, Yin WH (2019) SSTR2 is a useful diagnostic marker for follicular dendritic cells and their related tumors. Am J Surg Pathol 43:374–381

    Article  Google Scholar 

  4. Tao L, Chen Y, Huang Q, Yong J, Yan S, Huang Y (2019) Constant expression of somatostatin receptor 2a in minute pulmonary meningothelial-like nodules. J Clin Pathol 72:525–528

    Article  CAS  Google Scholar 

  5. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen PC, Højgaard L, Kjaer A (2010) Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy,123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 51:704–712

    Article  Google Scholar 

  6. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321–1325

    Article  CAS  Google Scholar 

  7. Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C (2014) Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTANOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin Nucl Med 39:e27–e34

    Article  Google Scholar 

  8. Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ (2016) 68Ga-DOTA-peptide: a novel molecular biomarker for nasopharyngeal carcinoma. Head Neck 38:E75–E80

    Article  Google Scholar 

  9. EI-Naggar AK (2017) In: JKC C, Grandis JR, Takata T, Slootweg PJ (eds) WHO classification of head and neck tumors, vol 9, 4th edn. IARC, Lyon, pp 66–68

    Google Scholar 

  10. Korner M, Waser B, Schonbrunn A, Perren A, Reubi JC (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242–252

    Article  Google Scholar 

  11. Mehta S, de Reuver PR, Gill P, Andrici J, D'Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ (2015) Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors. Medicine (Baltimore) 94:e1281

    Article  CAS  Google Scholar 

  12. Pazaitou-Panayiotou K, Tiensuu Janson E, Koletsa T, Kotoula V, Stridsberg M, Karkavelas G, Karayannopoulou G (2012) Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones 11:290–296

    Article  Google Scholar 

  13. Pilichowska M, Kimura N, Schindler M, Suzuki A, Yoshida R, Nagura H (2000) Expression of somatostatin type 2A receptor correlates with estrogen receptor in human breast carcinoma. Endocr Pathol 11:57–67

    Article  CAS  Google Scholar 

  14. Lequoy M, Desbois-Mouthon C, Wendum D, Gupta V, Blachon JL, Scatton O, Dumont S, Mireille Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L (2017) Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 70:492–498

    Article  Google Scholar 

  15. Zhao J, Liang Q, Cheung KF, Kang W, Dong Y, Lung RW, Tong JH, Ka Fai To KF, Sung JJ, Yu J (2013) Somatostatin receptor 1, a novel EBV-driven CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer. Br J Cancer 108:2557–2564

    Article  CAS  Google Scholar 

  16. Glaser R, Kutz LA, MacCallum RC, Malarkey WB (1995) Hormonal modulation of Epstein-Barr virus replication. Neuroendocrinology 62:356–361

    Article  CAS  Google Scholar 

  17. Carideo L, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, Annibale B, Signore A (2019) Role of combined [68Ga] Ga-DOTA-SST analogues and [18F] FDG PET/CT in the management of GEP-NENs: a systematic review. J Clin Med 8:E1032

    Article  Google Scholar 

  18. Loh KS, Waser B, Tan LK, Ruan RS, Stauffer E, Reubi JC (2002) Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch 441:444–448

    Article  CAS  Google Scholar 

  19. Pelosi G, Pasini F, Sonzogin A, Maffini F, Maisonneuve P, Iannucci A, Terzi A, De Manzoni G, Bresaola E, Viale G (2003) Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I non-small cell lung carcinoma. Cancer 97(10):2487–2497

    Article  Google Scholar 

  20. Feng J, Sheng H, Zhu C, Qian X, Wan D, Su D, Chen X, Zhu L (2016) Correlations of neuroendocrine features with prognosis of non-small cell lung cancer. Oncotarget 7(44):71727–71736

    Article  Google Scholar 

  21. Zhu R, Yang X, Xue X, Shen M, Chen F, Chen X, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y (2018) Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer. Biochim Biophys Acta Mol Cell Res 1865(12):1878–1890

    Article  CAS  Google Scholar 

  22. Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK (2017) Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (TKI-258) and its therapeutic implications. Transl Oncol 10(3):357–366

    Article  Google Scholar 

  23. Lee AW, Ma BB, Ng WT, Chan AT (2015) Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 33:3356–3364

    Article  Google Scholar 

  24. Prawira A, Oosting SF, Chen TW, Delos Santos KA, Saluja R, Wang L, Siu LL, Chan KKW, Hansen AR (2017) Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer 117:1743–1752

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported by Medical Science and Technology Program of Guangdong (2017116204155117), Medical Science and Technology Foundation of Guangdong Province (A2018001), and Natural Science Foundation of Guangdong Province (2018A030313663).

Author information

Author notes

  1. Weihua Yin and Yuhua Huang contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Peking University Shenzhen Hospital, 1116 Lianhua Road, Futian District, Shenzhen, 518000, Guangdong, People’s Republic of China

    Lili Tao, Yaoli Chen, Xiaoxin Shi, Guangyin Yu & Weihua Yin

  2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People’s Republic of China

    Yuhua Huang

  3. Department of Pathology, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, People’s Republic of China

    Yuhua Huang

Authors
  1. Lili Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaoli Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoxin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guangyin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weihua Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuhua Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Lili Tao performed interpretation of the data and drafted the manuscript. Yaoli Chen and Guangyin Yu performed hematoxylin and eosin and immunohistochemical staining. Xiaoxin Shi participated in the data collection. Weihua Yin performed histological analysis and immunohistochemical analysis. Yuhua Huang conceived the study, participated in its designand coordination and drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yuhua Huang.

Ethics declarations

The study was approved by the Institutional Review Board of Peking University Shenzhen Hospital, and all patients provided written informed consent for the collection and publication of their medical information during the first visit to our hospital.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, L., Chen, Y., Shi, X. et al. Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma. Virchows Arch 477, 573–579 (2020). https://doi.org/10.1007/s00428-020-02815-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-020-02815-7

Keywords

Search

Navigation